▲ Repaglinide is a novel insulin secretagogue being developed for the management of type 2 (non-insulin-dependent) diabetes mellitus. It stimulates release of insulin from the pancreatic β-cell, but appears to bind to a different receptor site from sulphonylureas.
▲ Repaglinide lowers fasting and postprandial blood glucose levels in animals, healthy volunteers and patients with type 2 diabetes mellitus.
▲ Repaglinide is rapidly absorbed and eliminated, which may allow a relatively fast onset and offset of action. Excretion occurs almost entirely by non-renal mechanisms.
▲ In comparative clinical trials in patients with type 2 diabetes mellitus, repaglinide 0.5 to 4mg twice or 3 times daily before meals provided similar glycaemic control to glibenclamide (glyburide) 2.5 to 15 mg/day. Addition of repaglinide to existing metformin therapy resulted in improved glycaemic control.
▲ In contrast with glibenclamide, use of repaglinide allowed patients to miss a meal without apparently increasing the risk of hypoglycaemia.
KeywordsMetformin Adis International Limited Glibenclamide Repaglinide Glimepiride
Unable to display preview. Download preview PDF.
- 2.Van Onderbergen A, Malaisse LF, Malaisse WJ. Failure of meglitinide analogues to augment Ba(2+)-induced insulin release. Med Sci Res 1995; 23 (6): 371–2Google Scholar
- 6.Fuhlendorff J, Carr RD, Kofod H. Repaglinide: unique mechanism of action in normal and metabolic stressed β cells [abstract]. Diabetologia 1995; 38 Suppl. 1: A195Google Scholar
- 10.Robling MR, Dolben J, Luzio SD. Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes mellitus (NIDDM) [abstract]. Br J Clin Pharmacol 1992 Aug; 34: 173PGoogle Scholar
- 12.Hedberg TG. Repaglinide: a double-blind, randomised, dose-response study. Abstract submitted to the 34th Annual Meeting of the- European Association for the Study of Diabetes; 1998 Sep 8–12: BarcelonaGoogle Scholar
- 13.Profozic V, Babic D, Renar I, et al. Benzoic acid derivative hypoglycaemic activity and pharmacokinetics in non-insulin dependent diabetic patients. Diab Croatica 1996; 25: 109–16Google Scholar
- 15.Oliver S, Windfeld K, Hatorp V. Pharmacokinetics and bioavailability of repaglinide, a new OHA for patients with NIDDM [abstract]. Diabetes 1997 May; 46 Suppl. 1: 331AGoogle Scholar
- 16.Hatorp V, Nielsen KK, Rathgen K, et al. Bioavailability of repaglinide after administration as either 2 mg tablet or 2 mg i.v. infusion [abstract]. J Clin Pharmacol 1997 Sep; 37: 874Google Scholar
- 17.Hatorp V, Bayer T. Repaglinide bioavailability in the fed or fasting state [abstract]. J Clin Pharmacol 1997 Sep; 37: 875Google Scholar
- 18.Perentesis GP, Damsbo P, Müller PG, et al. Single dose pharmacokinetics and pharmacodynamics of repaglinide in type II diabetic patients [abstract]. J Clin Pharmacol 1994 Oct; 34: 1021Google Scholar
- 19.Schwartz SL, Strange P. Repaglinide does not accumulate in patients with type 2 diabetes [abstract no. 1380]. Diabetes 1998; 47 Suppl. 1: A357Google Scholar
- 20.Van Heiningen PNM, Hatorp V, Van Lier JJ, et al. Disposition of one dose of 14C-repaglinide during non-labeled repaglinide multiple dosing [abstract no. 1374]. Diabetes 1998; 47 Suppl. 1: A355Google Scholar
- 21.Bauer E, Beschke K, Ebner T, et al. Biotransformation of [14C]repaglinide in human, cynomolgus monkey, dog, rabbit, rat and mouse [abstract]. Diabetologia 1997 Jun; 40 Suppl. 1: 326Google Scholar
- 22.Marbury TC, Hatorp V. Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers [abstract no. 1381]. Diabetes 1998; 47 Suppl. 1: A357Google Scholar
- 23.Hatorp V, Haug-Pihale G. A comparison of the pharmacokinetics of repaglinide in healthy sujects with that in subjects with chronic liver disease [abstract no. 1375]. Diabetes 1998; 47 Suppl. 1: A356Google Scholar
- 25.Landgraf R, Bilo H. Repaglinide vs glibenclamide: a 14-week efficacy and safety comparison [abstract]. Diabetes 1997 May; 46 Suppl. 1: 162AGoogle Scholar
- 26.Marbury TC, Strange P. Multicenter, randomized comparison of the therapeutic effects of long-term use of repaglinide with glyburide in type 2 diabetes [abstract no. 0292]. Diabetes 1998; 47 Suppl. 1: A75Google Scholar
- 27.Goldberg RB, Brodows RG, Damsbo P. A randomized, placebo-controlled trial of repaglinide in the treatment of type 2 diabetes [abstract no. 0383]. Diabetes 1998; 47 Suppl. 1: A98Google Scholar
- 28.Van Gaal LF, Van Acker KL, Damsbo P, et al. Metabolic effects of repaglinide, a new oral hypoglycaemic agent in therapy-naive type 2 diabetics [abstract]. Diabetologia 1995; 38 Suppl. 1: A43Google Scholar
- 29.Damsbo P, Andersen PH, Lund S, et al. Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing [abstract]. Diabetes 1997 May; 46 Suppl. 1: 34AGoogle Scholar
- 30.Tronier B, Marbury TC, Damsbo P, et al. A new oral hypoglycaemic agent, repaglinide minimises risk of hypoglycaemia in well controlled type 2 diabetic patients [abstract]. Diabetes 1995 May; 44 Suppl. 1: 70AGoogle Scholar
- 31.Moses R, Slobodniuk R, Donnelly T, et al. Additional treatment with repaglinide provides significant improvement in glycaemic control in NIDDM patients poorly controlled on metformin [abstract]. Diabetes 1997 May; 46 Suppl. 1: 93Google Scholar
- 32.Damsbo P, Perentesis G, Müller PG, et al. Favorable tolerability profile of repaglinide in NIDDM after multiple ascending doses [abstract]. J Clin Pharmacol 1997 Sep; 37: 875Google Scholar